BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 27245446)

  • 1. The biological function of antibodies induced by the RTS,S/AS01 malaria vaccine candidate is determined by their fine specificity.
    Chaudhury S; Ockenhouse CF; Regules JA; Dutta S; Wallqvist A; Jongert E; Waters NC; Lemiale F; Bergmann-Leitner E
    Malar J; 2016 May; 15():301. PubMed ID: 27245446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
    Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
    Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delayed fractional dose regimen of the RTS,S/AS01 malaria vaccine candidate enhances an IgG4 response that inhibits serum opsonophagocytosis.
    Chaudhury S; Regules JA; Darko CA; Dutta S; Wallqvist A; Waters NC; Jongert E; Lemiale F; Bergmann-Leitner ES
    Sci Rep; 2017 Aug; 7(1):7998. PubMed ID: 28801554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
    Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
    Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial.
    Kurtovic L; Atre T; Feng G; Wines BD; Chan JA; Boyle MJ; Drew DR; Hogarth PM; Fowkes FJI; Bergmann-Leitner ES; Beeson JG
    J Infect Dis; 2021 Oct; 224(7):1128-1138. PubMed ID: 32236404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opsonization by antigen-specific antibodies as a mechanism of protective immunity induced by Plasmodium falciparum circumsporozoite protein-based vaccine.
    Schwenk R; Asher LV; Chalom I; Lanar D; Sun P; White K; Keil D; Kester KE; Stoute J; Heppner DG; Krzych U
    Parasite Immunol; 2003 Jan; 25(1):17-25. PubMed ID: 12753434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction and decay of functional complement-fixing antibodies by the RTS,S malaria vaccine in children, and a negative impact of malaria exposure.
    Kurtovic L; Agius PA; Feng G; Drew DR; Ubillos I; Sacarlal J; Aponte JJ; Fowkes FJI; Dobaño C; Beeson JG
    BMC Med; 2019 Feb; 17(1):45. PubMed ID: 30798787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.
    Regules JA; Cicatelli SB; Bennett JW; Paolino KM; Twomey PS; Moon JE; Kathcart AK; Hauns KD; Komisar JL; Qabar AN; Davidson SA; Dutta S; Griffith ME; Magee CD; Wojnarski M; Livezey JR; Kress AT; Waterman PE; Jongert E; Wille-Reece U; Volkmuth W; Emerling D; Robinson WH; Lievens M; Morelle D; Lee CK; Yassin-Rajkumar B; Weltzin R; Cohen J; Paris RM; Waters NC; Birkett AJ; Kaslow DC; Ballou WR; Ockenhouse CF; Vekemans J
    J Infect Dis; 2016 Sep; 214(5):762-71. PubMed ID: 27296848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
    White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
    Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
    Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
    BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of the candidate RTS,S/AS01 vaccine in young Nigerian children: a randomized, double-blind, lot-to-lot consistency trial.
    Umeh R; Oguche S; Oguonu T; Pitmang S; Shu E; Onyia JT; Daniyam CA; Shwe D; Ahmad A; Jongert E; Catteau G; Lievens M; Ofori-Anyinam O; Leach A
    Vaccine; 2014 Nov; 32(48):6556-62. PubMed ID: 25077418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
    Chaudhury S; MacGill RS; Early AM; Bolton JS; King CR; Locke E; Pierson T; Wirth DF; Neafsey DE; Bergmann-Leitner ES
    Vaccine; 2021 Feb; 39(6):968-975. PubMed ID: 33431225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
    J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children.
    Feng G; Kurtovic L; Agius PA; Aitken EH; Sacarlal J; Wines BD; Hogarth PM; Rogerson SJ; Fowkes FJI; Dobaño C; Beeson JG
    BMC Med; 2022 Aug; 20(1):289. PubMed ID: 36002841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.
    von Seidlein L; Hanboonkunupakarn B; Jittamala P; Pongsuwan P; Chotivanich K; Tarning J; Hoglund RM; Winterberg M; Mukaka M; Peerawaranun P; Sirithiranont P; Doran Z; Ockenhouse CF; Ivinson K; Lee C; Birkett AJ; Kaslow DC; Singhasivanon P; Day NPJ; Dondorp AM; White NJ; Pukrittayakamee S
    Hum Vaccin Immunother; 2020; 16(1):33-41. PubMed ID: 31306084
    [No Abstract]   [Full Text] [Related]  

  • 17. Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria.
    Olotu A; Moris P; Mwacharo J; Vekemans J; Kimani D; Janssens M; Kai O; Jongert E; Lievens M; Leach A; Villafana T; Savarese B; Marsh K; Cohen J; Bejon P
    PLoS One; 2011; 6(10):e25786. PubMed ID: 21998698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional correlates of malaria in RTS,S/AS01-vaccinated African children: a matched case-control study.
    Moncunill G; Carnes J; Chad Young W; Carpp L; De Rosa S; Campo JJ; Nhabomba A; Mpina M; Jairoce C; Finak G; Haas P; Muriel C; Van P; Sanz H; Dutta S; Mordmüller B; Agnandji ST; Díez-Padrisa N; Williams NA; Aponte JJ; Valim C; Neafsey DE; Daubenberger C; McElrath MJ; Dobaño C; Stuart K; Gottardo R
    Elife; 2022 Jan; 11():. PubMed ID: 35060479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
    Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
    J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RTS,S/AS01
    Suau R; Vidal M; Aguilar R; Ruiz-Olalla G; Vázquez-Santiago M; Jairoce C; Nhabomba AJ; Gyan B; Dosoo D; Asante KP; Owusu-Agyei S; Campo JJ; Izquierdo L; Cavanagh D; Coppel RL; Chauhan V; Angov E; Dutta S; Gaur D; Beeson JG; Moncunill G; Dobaño C
    Vaccine; 2021 Jan; 39(4):687-698. PubMed ID: 33358704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.